In the May 1995 issue of the Archives, we reported1 the efficacy of high-dose recombinant interleukin-2 in the treatment of 7 patients with advanced cutaneous T-cell lymphoma (CTCL). In January 1994, we observed 3 patients with complete remissions and 2 with progressive disease as a result of this treatment. Two patients of the 7 had already died of their lymphomas. In this letter, we report the evolution of the 5 remaining patients as of November 1996.
The 2 patients whose disease was progressive died as a result of their lymphomas (patient 5 in January 1994 and patient 4 in July 1994). Patient 7 relapsed in March